First oral CGRP-subject antagonist migraine drug! El Jian ubrogepant will submit a listing application in early 2019:
Time of Update: 2021-02-14
Allergan recently announced that it has completed two clinical studies of ubrogepant for acute migraine treatment and has obtained positive safety and tolerance data. first study (UBR-MD-04) assessed the long-term safety and tolerance
Neurology: Angiotensin II stimulates antihypertensive drugs, or helps prevent dementia
Time of Update: 2021-01-17
other antihypertensive drugs, the subcatfacies most associated with reducing the risk of dementia are angiotensin blockers, certain calcium channel blockers, and diuretics.
Identification of Adipokine Receptor Agonists and Turning Them to Antagonists
Time of Update: 2020-12-17
A recent discovery and design process for leptin and adiponectin receptorresponse modifier peptides can be generalized to a series of transmembrane receptor ligands.
New drug for uterine fibroids! Best-in-class GnRH subject antagonist linzagolix EU applied for listing
Time of Update: 2020-12-14
results showed that both trials had successfully reached the main endpoint: A significant statistical and clinical reduction in HMB in all dose groups compared to placebos.
Chemokine Receptor Antagonist Development
Time of Update: 2020-12-08
This chapter describes assays that focus on the characterization of compounds identified in high-�throughput screening campaigns,and the subsequent medicinal chemistry programs. They cover methods to determine potency in buffer
New migraine drug! AbbVie oral CGRP receptor antagonist atogepant prevention migraine Phase III clinical success!
Time of Update: 2020-08-06
data showed that all atogepant dose groups reached the primary endpoint and that the average number of migraine days per month was statistically significantly reduced compared to placebos.
Adenosine inhibitors immuno-micro-environment-regulating drugs for tumors (I) : A2aR antagonists.
Time of Update: 2020-08-01
AZD4635 related clinical trials 3 CPI-444 CPI-444 developed by Corvus and Roche, currently nSCLC indications into Phase II clinical indications have NSCLC, its clinical use strategy includes single drug, with PD-L1 mono-resistance, with CD73 mono-resistance, and CD38 mono-resistance combination.
New anti-transplant drugs! IL-2 Receptor Targeting Immunotherapy Leukotac is on the market
Time of Update: 2020-07-31
application (BLA) for the treatment of patients with SR-aGvin disease in the class II-IV steroid refractive acute transplantation (SR-aGv). the BLA will be reviewed through the FDA Real-Time Oncology Review Pilot Program (RTOR), an initiative
Oral GnRH receptor antagonists for endometriosis Phase 2 Clinical End.
Time of Update: 2020-07-20
On June 23, Myovant Sciences published the top-line results of the SPIRIT 1 study, the second phase III study to evaluate the relugolix combination therapy (relugolix 40mg plus estradiol 1.0mg plus acetate ketone 0.5mg) to treat pain associated
A new drug for specific dermatitis (AD) itching! New anti-inflammatory drug: IL-31 receptor
Time of Update: 2020-07-17
the percentage of patients with a quality of life index (DLQI) score of 4, 40 percent in the nemolizumab group and 22 percent in the placebo group.
Gupon: Angiotensin conversion enzyme inhibitors/angiotensin receptor blockers associated with lower risk of colorectal cancer
Time of Update: 2020-07-14
The risk ratio for colorectal cancer, adjusted by ACE inhibitor/angiotensin receptor blockers, was derived by matching score regression on 23 covariates, including patient factors, simultaneous medication, and endoscopic center performance.
New drugs for insomnia! The eludant of ego receptor seroinion, Dayvigo (lemborexant), is on the market in Hong Kong, China!
Time of Update: 2020-07-14
, July 09, 2020 / bio-valley smh.com.au/Eisai has announced that a new drug application for its insomnia drug Dayvigo (lemborexant) has been accepted by the Hong Kong Special Administrative Region Of China Health Department
A new HIV-1 receptor may become a target for the development of new AIDS drugs
Time of Update: 2020-07-04
Integrator alpha4 beta7 is a normal component of human cells, located in the mucous membrane of the digestive tract, and is the peripheral T-cell nesting receptor.
EU approves type 2 diabetes drug GLP-1 receptor agonist Rybelsus
Time of Update: 2020-06-25
Novo Nordisk today announced that the European Medicines Agency (EMA) has approved the sale of the company's oral GLP-1 receptor agonisant Rybelsus (semaglutide) to help control blood sugar in people with type 2 diabetes.
Phase 3 clinical studies have confirmed that the gonadotropin-releasing hormone (GnRH) receptor
Time of Update: 2020-06-22
in spirit 2 results analysis, 75.2% of women who received relugolix combination therapy achieved clinically meaningful improvements in menstruation, compared with 30.4% in the placebo group (p 0.0001).
New drugs for insomnia! The eludant of ego receptor serombia is available in the United States!
Time of Update: 2020-06-17
, June 04, 2020 / PRNewswire/ -- Eisai, a Japanese pharmaceutical company, recently announced the launch of the new insomnia drug Dayvigo (lerexmboant) CIV in the U.S. market, which comes in two sizes (5mg and 10mg tablets
Adenosine inhibitors immuno-micro-environmental regulatory drugs for tumors (I) : A2aR antagonists
Time of Update: 2020-06-15
, AZD4635 was developed by AstraZeneca and currently has prostate cancer and NSCLC and other indications into Phase II clinical, its clinical use strategy includes single drug, with PD-L1 monoantiphoresis, and CD73 monotonica.
FDA accepts new drug application from androgen receptor (AR) antagonist darolutamide
Time of Update: 2020-06-09
FDA ( accepted the company's application for new drug ( (NDA) for the androgen receptor (AR) antagonist darolutamide for the treatment of non-metastatic resistance prostate cancer (CRNM).
Her reached primary and secondary endpoints in the 3rd phase of the study of GnRH receptor antagonist relugolix
Time of Update: 2020-06-07
today, Myovant Sciences company ( announced that it has reached the primary and all critical secondary endpoints in the Phase 3 study HERO for the treatment of patients with advanced prostate cancer.
5th approval! Lilly's anti-inflammatory drug Taltz is approved by the U.S. FDA: the first IL-17A
Time of Update: 2020-06-05
June 02, 2020 / Biovalley BIOON/ -- Lilly recently announced that the U.S. Food and Drug Administration ( FDA ) has approved taltz ( 80mg/mL injection) a new indication for the treatment